November 1, 2021

ANI Pharmaceuticals has announced U.S. FDA approval of the company’s Purified Cortrophin™ Gel (repository corticotropin injection). The product is indicated to treat certain rheumatic disorders, collagen diseases, dermatologic diseases, allergic states, ophthalmic diseases, respiratory diseases, proteinuria, and acute exacerbations of multiple sclerosis.

  • Recommended dosing is based on factors that include the indication, severity of disease, and general medical condition of the patient. Purified Cortrophin Gel is administered either subcutaneously or intramuscularly and can be self-administered or administered by a caregiver.
  • ANI Pharmaceuticals plans to launch the drug during the first quarter of 2022. Pricing is not yet available.
January 3, 2022

FDA Expands Comirnaty Authorization to Prevent COVID-19

Read More
December 23, 2021

Merck’s COVID-19 Antiviral Granted Emergency Use Authorization

Read More
December 22, 2021

FDA Authorizes First Oral Antiviral for COVID-19

Read More
December 20, 2021

Xarelto Approved to Treat and Prevent Blood Clots in Children

Read More